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Abstract
A total of 410 patients with blast phase myeloproliferative neoplasm (MPN-BP) were retrospectively reviewed: 248 from the
Mayo Clinic and 162 from Italy. Median survival was 3.6 months, with no improvement over the last 15 years. Multivariable
analysis performed on the Mayo cohort identiﬁed high risk karyotype, platelet count< 100× 109/L, age> 65 years and
transfusion need as independent risk factors for survival. Also in the Mayo cohort, intensive chemotherapy resulted in complete
remission (CR) or CR with incomplete count recovery (CRi) rates of 35 and 24%, respectively; treatment-speciﬁed 3-year/5-year
survival rates were 32/10% for patients receiving allogeneic stem cell transplant (AlloSCT) (n= 24), 19/13% for patients
achieving CR/CRi but were not transplanted (n= 24), and 1/1% in the absence of both AlloSCT and CR/CRi (n= 200) (p<
0.01). The survival impact of AlloSCT (HR 0.2, 95% CI 0.1–0.3), CR/CRi without AlloSCT (HR 0.3, 95% CI 0.2–0.5), high risk
karyotype (HR 1.6, 95% CI 1.1–2.2) and platelet count< 100× 109/L (HR 1.6, 95% CI 1.1–2.2) were conﬁrmed to be inter-
independent. Similar observations were made in the Italian cohort. The current study identiﬁes the setting for improved short-term
survival in MPN-BP, but also highlights the limited value of current therapy, including AlloSCT, in securing long-term survival.
Introduction
The World Health Organization (WHO) classiﬁcation sys-
tem currently recognizes four variants of myeloproliferative
neoplasms (MPN) associated with JAK2, CALR or MPL
mutations: primary myeloﬁbrosis (PMF), preﬁbrotic PMF
(pre-PMF), essential thrombocythemia (ET) and poly-
cythemia vera (PV); [1] in addition, 5–30% patients with
ET or PV experience ﬁbrotic progression of their disease
over time, referred to as post-ET and post-PV myeloﬁbrosis,
respectively [2]. All of these MPN variants might evolve
into blast phase disease (MPN-BP), operationally deﬁned
by the presence of ≥20% blasts in the blood or bone marrow
[1]. The risk of leukemic transformation in MPN depends
on the MPN variant and is highest in PMF, with an inci-
dence of 10–20%, in the ﬁrst 10 years of the disease, lower
in PV, with estimated risk of 3% at 10 years and 8% at 20
years, and lowest in ET with less than 1% risk in the ﬁrst
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decade of disease [3–6]. Leukemic transformation rates do
not appear to be different between PMF and ﬁbrotic phases
of PV or ET and the latter can transform directly into MPN-
BP without going through a ﬁbrotic disease phase [7–9].
Reported risk factors for leukemic transformation in
PMF include unfavorable karyotype, especially monosomal
karyotype, thrombocytopenia, excess circulating blasts,
marked leukocytosis, transfusion-requiring anemia, older
age and increased levels of serum interleukin-8 and C-
reactive protein; [10–15] also in play are both driver and
other mutations, where triple-negative driver mutational
status and presence of ASXL1, SRSF2, IDH1/2, RUNX1,
CEBPA or SH2B3 mutations have been associated with
higher and CALR type 1-like mutation with lower risk of
leukemic transformation [3, 16–20]. Risk factors reported
for leukemic transformation in PV include leukocytosis,
older age, abnormal karyotype, presence of SRSF2 or IDH2
mutations and treatment with radiophosphorous, chlor-
ambucil or pipobroman [6, 21–25]. In ET, accurate mor-
phologic diagnosis is critical in assessing leukemia risk,
because of the need to distinguish between strictly WHO-
deﬁned ET and pre-PMF; [4] reported risk factors for leu-
kemic transformation have included anemia, extreme
thrombocytosis, older age, leukocytosis, and presence of
TP53 or EZH2 mutations [4, 25–30].
Prognosis in MPN-BP is extremely poor; in an earlier
study of 91 patients, we had reported a median survival of
less than 3 months for patients receiving supportive care
only and approximately 6 months for those receiving acute
myeloid leukemia (AML)-like induction chemotherapy [7].
The dismal prognosis of MPN-BP has also been highlighted
by other more recent studies where speciﬁc treatment did
not appear to inﬂuence either progression-free or overall
survival whereas patients receiving allogeneic stem cell
transplant (AlloSCT) in complete remission (CR) might
have achieved signiﬁcantly longer survival [31]. The pos-
sibility of longer survival with AML-like induction che-
motherapy and AlloSCT has also been reported by others,
although inconsistently [31]. In the current study, we ret-
rospectively reviewed consecutive cases of MPN-BP from
the institutional databases of the Mayo Clinic, Rochester,
MN, USA and the AIRC-Gruppo Italiano Malattie Mielo-
proliferative (AGIMM), with the intent to examine (i) recent
survival trends, (ii) treatment outcome, including response
rates to treatments received for blast phase disease and (iii)
risk factors for survival, including the impact of che-
motherapy and AlloSCT.
Methods
The current study constitutes a retrospective review of
consecutive cases of MPN-BP, where diagnoses of
leukemic transformation and the antecedent MPN were
conﬁrmed by both clinical and bone marrow examinations,
in line with the WHO criteria [1]. Study patients were
recruited from institutional databases of the Mayo Clinic,
Rochester, MN, USA and the AGIMM, after approval from
the respective institutional review boards. The two patient
cohorts were analyzed separately and not combined. The
Mayo Clinic cohort constituted the central core and the
Italian cohort was used to conﬁrm some of the important
observations from the Mayo cohort. Both patient cohorts
also examined survival trends over the last 15 years whereas
an even earlier period was also considered in the Mayo
cohort analysis, based on availability of information on
patients diagnosed earlier. Estimates for chemotherapy-
induced complete remission (CR) and CR with incomplete
blood count recovery (CRi) rates were obtained for both
patient cohorts. However, a more detailed analysis of risk
factors and treatment-speciﬁed outcome data was per-
formed, mostly on the Mayo patient cohort, based on ease
of access to centralized data.
Clinical and laboratory data, including cytogenetic
information, were collected from patients at the time of
leukemic transformation. Cytogenetic analysis and report-
ing was done according to the International System for
Human Cytogenetic Nomenclature criteria. For the pur-
poses of the current study, and based on previously estab-
lished prognostic relevance [32], the following cytogenetic
abnormalities were identiﬁed as being “high risk”: mono-
somal karyotype and single or multiple abnormalities of −7,
inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2) and i(17)(q10).
Survival was calculated from time of leukemic transfor-
mation, commensurate with time of cytogenetic analysis,
and collection of clinical and laboratory parameters exam-
ined for impact on survival. Standard statistical methods
were used to determine signiﬁcance of differences among
groups in the distribution of continuous or nominal vari-
ables. Overall survival data were prepared by the
Kaplan–Meier method and compared by the log–rank test.
Cox proportional hazard regression model was applied for
multivariable analysis. P-value< 0.05 was considered sig-
niﬁcant. The Stat View (SAS Institute, Cary, NC, USA)
statistical package was used for all calculations.
Results
Patient characteristics at time of leukemic
transformation
The Mayo Clinic cohort included 248 consecutive patients
(median age 67 years; 65% males) with MPN-BP, including
118 (48%) post-PMF and 130 (52%) post-PV/ET MPN-BP;
among the latter, 60 patients had post-PV (32 without
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documented MF phase) and 70 post-ET (39 without docu-
mented MF phase) MPN-BP (Table 1). Bone marrow
examination morphology reports included 103 (42%)
patients with acute myeloid leukemia, not otherwise speci-
ﬁed (AML-NOS), 64 (26%) with AML with
myelodysplasia-related changes, 17 (7%) with AML-NOS-
M7, 14 (6%) with AML-NOS-M2, 12 (5%) with
AML-NOS-M5, 10 (4%) with AML-NOS-M4, 8 (3%) with
AML-NOS-M0, 6 (2%) with AML-NOS-M1, 3 (1%) with
AML-NOS-M6 and 3 (1%) with AML with recurrent
favorable cytogenetic abnormalities; 8 (3%) patients pre-
sented with myeloid sarcoma. Among all evaluable cases, at
the time of leukemic transformation, 34% displayed red cell
transfusion need, 58% platelet count< 100× 10(9)/l, 37%
leukocyte count> 25× 10(9)/l, 71% circulating blasts ≥
20%, 87% bone marrow blasts ≥ 20 and 68% JAK2V617F
mutation (Table 1). Cytogenetic information was available
in 172 cases, out of which 140 (81%) were reported out as
abnormal and 19% (n= 32) normal; among the 140
abnormal cases, 56 (40%) were labelled as “high risk”,
based on the presence of monosomal karyotype or monos-
omy 7 (n= 46) or single or multiple abnormalities includ-
ing inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2) (n= 5), or i(17)
(q10) (n= 5).
Compared to post-PMF MPN-BP, post-PV/ET MPN-BP
cases displayed female preponderance (p= 0.04), lower
percentage of red cell transfusion need (p= 0.0004), higher
platelet count (p= 0.004) and lower circulating blast per-
centage (p= 0.005) (Table 1). Cytogenetic proﬁle and
prevalence of JAK2V617F mutation were similar between
post-PMF and post-PV/ET MPN-BP (Table 1).
The AGIMM cohort consisted of 162 consecutive
patients (median age 69 years; 57% males) with MPN-BP,
including 70 (43%) post-PMF MPN-BP and 92 (57%) post-
PV/ET MPN-BP; among the latter, 37 patients had post-PV
(14 without documented MF phase) and 52 post-ET (30
Table 1 Clinical and laboratory characteristics of 248 patients with blast phase myeloproliferative neoplasms at the time of leukemic
transformation
Variables All patients
(n= 248)
Post-PMF AML
(n= 118)
Post-PV/ET AMLa
(n= 130)
P-value
Age in years; median (range) 67 (40–90) 67 (40–87) 68 (42–90) 0.3
Age> 65 years; n (%) 140 (56) 63 (53) 77 (59) 0.4
Sex (male); n (%) 161 (65) 84 (71) 77 (59) 0.04
Transfusion dependent; n (%) “N” evaluable= 233 80 (34) 51 (46) 29 (24) 0.0004
Hemoglobin, g/dl; median (range) “N” evaluable= 217 9.3 (0.7–18.1) 9 (6.1–13.7) 9.5 (0.7–18.1) 0.05
Platelets x 109/L; median (range) “N” evaluable= 216 78 (3–2051) 69 (4–670) 100 (3–2051) 0.004
Platelets < 100× 109/L; n (%) “N” evaluable= 216 126 (58) 68 (69) 58 (50) 0.004
Leukocytes x 109/L; median (range) “N” evaluable= 218 15.9 (0.4–600) 22.2 (0.5–154) 14.3 (0.4–600) 0.09
Leukocytes > 25× 109/L; n (%) “N” evaluable= 218 81 (37) 42 (42) 39 (33) 0.2
Circulating blasts %; median (range) “N” evaluable= 215 26 (0–99) 29 (1–99) 22 (0–89) 0.005
Circulating blasts ≥ 20%; n (%) “N” evaluable= 215 152 (71) 77 (77) 75 (65) 0.06
Bone marrow blasts %; median (range) “N” evaluable= 180 33 (1–97) 36 (2–97) 30 (1–91) 0.09
Bone marrow blasts ≥ 20%; n (%) “N” evaluable= 180 156 (87) 64 (86) 92 (87) 0.9
ANC, x 109/L; median (range) “N” evaluable= 207 4.9 (0–68.9) 5.4 (0–56.1) 4.3 (0.1–68.9) 0.98
AMC, x 109/L; median (range) “N” evaluable= 204 0.7 (0–36.2) 0.7 (0–25.3) 0.7 (0–36.2) 0.45
Karyotype “N” evaluable= 172 Normal; n (%) Abnormal; n (%) 32 (19) 140 (81) 18 (23) 59 (77) 14 (15) 81 (85) 0.3
JAK2 mutated; n (%) “N” evaluable= 144 98 (68) 35 (60) 63 (73) 0.1
Allogeneic stem cell transplant; n (%) 24 (11) 9 (8) 15 (13) 0.3
Follow up in months; median (range) 3.6 (0–122) 3.3 (0–72) 4 (0–122) 0.7
Deaths; n (%) 239 (96) 115 (97) 124 (95) 0.4
AML acute myeloid leukemia, PMF primary myeloﬁbrosis, PV polycythemia vera, ET essential thrombocythemia, ANC absolute neutrophil count,
AMC absolute monocyte count, JAK2 Janus kinase 2
a Post PV AML patients, N= 60
Post PV AML without myeloﬁbrosis phase, N= 32
Post PV AML with myeloﬁbrosis phase, N= 28
Post ET AML patients, N= 70
Post ET AML without myeloﬁbrosis phase, N= 39
Post ET AML with myeloﬁbrosis phase, N= 31
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without documented MF phase) MPN-BP; antecedent MPN
was not veriﬁed in 3 cases. Among all evaluable cases in the
AGIMM cohort, at the time of leukemic transformation,
37% displayed red cell transfusion need, 55% platelet count
< 100× 10(9)/L, 36% leukocyte count > 25× 10(9)/L,
61% circulating blasts ≥ 20%, 97% bone marrow blasts ≥
20%, 61% abnormal karyotype and 61% JAK2V617F
mutation.
Survival trends over time
In the Mayo Clinic cohort, after a median follow-up of
3.6 months (range 0–122), 239 (96.4%) deaths were
recorded. Median survival was 3.6 months with 1, 3, and 5-
year survival rates of 17, 6, and 4%, respectively; survival
trends appeared signiﬁcantly better for patients diagnosed in
the year 2000 and afterwords, but with no additional
improvement in the last 15 years (Fig. 1a); median survival
of patients diagnosed with MPN-BP prior to the year 2000
vs in the years 2000–2009 vs in 2010 and afterwards was
2.3 (1-year and 3-year survival rates of 5 and 0%) vs 3.5 (1-
year and 3-year survival rates of 17 and 4%) vs 4.9 months
(1-year and 3-year survival rates of 20 and 10%), respec-
tively (p= 0.002); survival was similar for the diagnosis
period of 2010 and afterwards vs 2000–2009 (p= 0.27;
Fig. 1a). The AGIMM cohort was followed for a median of
3 months (range 0–127) and median survival was
3.6 months with 1 and 3-year survival rates of 25 and 11%,
respectively; as was the case with the Mayo cohort, survival
trends were not signiﬁcantly different according to year of
diagnosis, for patients diagnosed after the year 2000 (p=
0.9; Fig. 1b).
Overall management strategies and predictors of
treatment response
Treatment records were reviewed in detail for the 248 Mayo
Clinic patients; 121 (49%) were managed with supportive
care only, including the use of hydroxyurea for control of
leukocytosis, 79 (32%) were treated with a variety of che-
motherapeutic agents that were considered to be more
intensive than hydroxyurea, but failed to show a response,
24 (10%) received AlloSCT and 24 (10%) achieved
chemotherapy-induced CR or CR with incomplete blood
count recovery (CRi) but were not subsequently trans-
planted (Table 2); among the 24 transplanted patients, 16
were in CR/CRi at the time of AlloSCT while 8 received
AlloSCT either directly without pre-transplant induction
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Fig. 1 a Survival data on 248 Mayo Clinic patients with blast-phase myeloproliferative neoplasm, stratiﬁed by year of diagnosis; b Survival data
on 162 Italian patients with blast-phase myeloproliferative neoplasm, stratiﬁed by year of diagnosis
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chemotherapy or failed to achieve CR/CRi before transplant
(Table 2). Comparison of the baseline clinical character-
istics, among the different treatment and response cate-
gories, revealed signiﬁcant differences, only in age
distribution (Table 2).
A total of 125 Mayo Clinic patients received che-
motherapy that was considered to be more intensive than
hydroxyurea; 69 were treated with AML-like induction
chemotherapy, of whom 66 were evaluable for response, 26
with HMA and 30 with other drugs, including investiga-
tional agents. The AML-like induction chemotherapy in the
66 evaluable for response patients included idarubicin/
cytarabine-based “7+ 3” regimen in 40 patients, daunor-
ubicin/cytarabine-based “7+3” regimen in 13 patients,
“cytarabine + itoxantrone + etoposide” in 4 patients,
“daunorubicin + cytarabine + nilotinib” in 2 patients,
Table 2 Clinical and laboratory characteristics of 248 patients with blast phase myeloproliferative neoplasms at the time of leukemic
transformation, stratiﬁed by their overall management and response categories
Variables All patients
(n= 248)
Patients not
transplanted and
received
supportive care
only (n= 121)
Patients not
transplanted but
received
chemotherapy
with no response
(n= 79)
Patients not
transplanted but
achieved CR/
CRi with
chemotherapy
(n= 24)
Patients
transplanted
directly or after
failing
chemotherapy
(n= 8)
Patients
transplanted in
CR or CRi with
pre-transplant
chemotherapy
(n= 16)
P-value
Age in years; median
(range)
67 (40–90) 70 (40–90) 66 (46–90) 63 (45–82) 57 (44–68) 56 (42–70) <0.0001
Age> 65 years; n (%) 140 (56) 87 (72) 42 (53) 9 (38) 1 (13) 1 (6) <0.0001
Sex (male); n (%) 161 (65) 80 (66) 52 (66) 13 (54) 6 (75) 10 (63) 0.8
Transfusion dependent; n
(%) “N” evaluable= 233
80 (34) 41 (38) 31 (39) 4 (17) 2 (29) 2 (13) 0.08
Hemoglobin, g/dl; median
(range) “N” evaluable= 217
9.3 (0.7–18.1) 9.4 (5.8–14.1) 8.9 (0.7–14.5) 9.5 (6.3–15.8) 8.7 (7.9–14.1) 9.6 (6.9–18.1) 0.7
Platelets x 109/L; median
(range) “N” evaluable= 216
78 (3–2051) 77 (3–2051) 80 (6–691) 109 (11–1246) 73 (43–1126) 67 (15–412) 0.9
Platelets < 100× 109/L; n
(%) “N” evaluable= 216
126 (58) 62 (61) 41 (59) 11 (48) 3 (60) 9 (56) 0.9
Leukocytes x 109/L; median
(range) “N” evaluable= 218
15.9
(0.4–600)
15.5 (0.5–145.5) 22.3 (0.6–151.1) 14.6 (0.4–600) 55.1 (2.1–154.1) 5.8 (1.6–56.8) 0.1
Leukocytes > 25× 109/L; n
(%) “N” evaluable= 218
81 (37) 37 (36) 30 (42) 8 (35) 3 (60) 3 (19) 0.4
Circulating blasts %;
median (range) “N”
evaluable= 215
26 (0–99) 27 (0–88) 26 (0–99) 31 (0–76) 22 (10–89) 22 (10–76) 0.9
Circulating blasts ≥ 20%; n
(%) “N” evaluable= 215
152 (71) 74 (73) 49 (69) 15 (68) 3 (60) 11 (69) 0.9
Bone marrow blasts %;
median (range) “N”
evaluable= 180
33 (1–97) 34 (3–95) 30 (1–97) 47 (5–92) 29 (8–58) 32 (8–79) 0.3
Bone marrow blasts ≥ 20%;
n (%) “N” evaluable= 180
156 (87) 69 (90) 53 (84) 20 (91) 3 (75) 11 (79) 0.6
Karyotype “N” evaluable=
172 Normal; n (%)
Abnormal; n (%)
32 (19) 140
(81)
9 (13) 59 (87) 15 (25) 46 (75) 3 (14) 19 (86) 2 (40) 3 (60) 3 (19) 13 (81) 0.3
JAK2 mutated; n (%) “N”
evaluable= 144
98 (68) 36 (71) 37 (67) 12 (75) 4 (57) 9 (60) 0.8
Allogeneic stem cell
transplant; n (%) “N”
evaluable= 228
24 (11) 0 (0) 0 (0) 0 (0) 8 (100) 16 (100) <0.0001
Follow up in months;
median (range)
3.6 (0–122) 1.6 (0–59.9) 4.0 (0.2–70.7) 8.7 (1.7–71.6) 25.8 (7.9–122) 22.6 (7.8–55) <0.0001
Deaths; n (%) 239 (96) 119 (98) 79 (100) 21 (88) 7 (88) 13 (81) 0.0002
ANC absolute neutrophil count, AMC absolute monocyte count, JAK2 Janus kinase 2, CR complete remission, CRi CR with incomplete blood
count recovery
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“daunorubicin + cytarabine + etoposide” in 2 patients,
cytarabine only in 2 patients, “daunorubicin + cytarabine +
zosquidar” in 1 patient, “ﬂudarabine + cytarabine + G-CSF
+ idarubicin” in 1 patient and “ﬂudarabine + cytarabine +
mitoxantrone” in 1 patient.
The respective CR rates for AML-like induction che-
motherapy, HMA and other investigational drugs were 35,
4, and 3%; an additional 24% of patients who received
AML-like induction chemotherapy achieved CRi, which
was not observed in patients treated with HMA. In other
words, the likelihood of obtaining CR/CRi was 59% fol-
lowing AML-like induction chemotherapy vs <5% with
HMA or other agents. Additional analysis of the 66 patients
treated with AML-like induction chemotherapy and were
evaluable for response revealed no signiﬁcant associations
between the achievement of CR, CRi or no response with
any other clinical or laboratory parameter, including age
(p= 0.09), interval between MPN and MPN-BP diagnosis
(p= 0.3), leukocyte count (p= 0.6), platelet count
(p= 0.11), peripheral blood blast percentage (p= 0.77),
bone marrow blast percentage (p= 0.28), presence or
absence of high risk karyotype (p= 0.98), presence or
absence of abnormal karyotype (p= 0.72), presence or
absence of a JAK2 mutation (p= 0.15), antecedent MPN
type (p= 0.26) or WHO morphological category
(p= 0.37).
In the AGIMM patient cohort of 162 patients, 51 were
reported to have received AlloSCT (n= 25) or intensive
induction chemotherapy without AlloSCT (n= 26); a
total of 48 patients received intensive induction che-
motherapy that resulted in CR rate of 27.1% and CRi rate of
8.3%. AlloSCT in the Mayo cohort was reported in 24
Table 3 Univariate and multivariable analysis of survival in 248 patients with blast phase myeloproliferative neoplasms; all variables were
collected at time of leukemic transformation
Variables Univariate analysis Multivariable analysis
Hazard
ratio
95% conﬁdence
interval
P-value Hazard
ratio
95% conﬁdence
interval
P-value
Age in years <0.001
Age> 65 years 1.5 1.1–1.9 0.003 1.6 1.2–2.2 0.004
Sex (male) 1.1 0.8–1.4 0.5
MPN-MPN-BP intervala 0.11
Transfusion dependent “N” evaluable= 233 1.6 1.2–2.1 0.002 1.6 1.1–2.2 0.01
Hemoglobin, g/dl “N” evaluable= 217 0.1
Platelets x 109/L “N” evaluable= 216 0.01
Platelets < 100× 109/L “N” evaluable= 216 1.5 1.1–2.0 0.004 1.5 1.1–2.1 0.02
Leukocytes x 109/L “N” evaluable= 218 0.3
Leukocytes > 25× 109/L “N” evaluable= 218 1.1 0.8–1.5 0.5
Circulating blast % “N” evaluable= 215 0.8
Circulating blasts ≥ 20% “N” evaluable= 215 0.9 0.7–1.3 0.7
Bone marrow blast % “N” evaluable= 180 0.4
Bone marrow blasts ≥ 20% “N” evaluable= 180 1.4 0.9–2.3 0.1
WHO morphologic categoryb 0.06
Karyotype “N” evaluable= 172
Abnormal (n= 140; 81%) 1.5 1.0–2.3 0.046 1.8 1.3–2.6 0.001
“High risk” karyotypec (n= 83; 59%) 1.7 1.2–2.4 0.002
JAK2-mutated “N” evaluable= 144 1.1 0.7–1.6 0.6
MPN-BP variants
Post-PMF MPN-BP 1.4 0.99–1.9 0.06
Post-ET MPN-BP 1.4 1.0–2.1 0.04
Post-PV MPN-BP ref ref ref
MPN-BP blast phase myeloproliferative neoplasm, PMF primary myeloﬁbrosis, JAK2 Janus kinase 2, PV polycythemia vera, ET essential
thrombocythemia, WHO world health organization
a Interval between initial diagnosis of MPN and leukemic transformation
b Considering morphologic categories cited in at least 10 patients
c High risk karyotype included monosomal karyotype, monosomy 7 or single or multiple abnormalities including inv(3)(q21.3q26.2)/t(3;3)(q21.3;
q26.2)/i(17)(q10)
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patients, of whom 16 had received AML-like induction
chemotherapy and were transplanted in either CR (n= 10)
or CRi (n= 6) while the other 8 were transplanted either
directly without pre-transplant chemotherapy or after failing
such therapy.
Survival analysis and risk factors
Detailed survival analysis and examination of risk factors
for survival was performed on the Mayo cohort, where only
9 (3.6%) of the 248 study patients currently remain alive.
Table 3 outlines results of univariate and multivariable
analyses of variables collected at time of leukemic trans-
formation. Multivariable analysis of such baseline data
identiﬁed high risk karyotype, platelet count < 100× 109/L,
age> 65 years and red cell transfusion need as independent
risk factors for survival; the respective HR (95% CI) were
1.8 (1.3–2.6), 1.5 (1.1–2.1), 1.6 (1.2–2.2), and 1.6
(1.1–2.2). In addition, both age and platelet count remained
signiﬁcant when analyzed as continuous variables and
karyotype classiﬁed simply as normal vs abnormal (data not
shown). Noteworthy in their lack of survival effect included
antecedent MPN type and WHO morphological category
(data not shown).
Next, we analyzed the effect of speciﬁc treatment stra-
tegies and response categories on survival. One-year/3-year/
5-year survival rates were 66/32/10% for patients receiving
AlloSCT (n= 24), 37/19/13% for patients achieving
CR/CRi but were not transplanted (n= 24), and 8/1/1% in
the absence of both AlloSCT and CR/CRi (n= 200)
(p< 0.01; Fig. 2a); HR (95% CI) were 0.2 (0.1–0.3) for
transplant vs no transplant/no CR/CRi; 0.3 (0.2–0.5) for
CR/CRi without transplant vs no transplant/no CR/CRi; 0.6
(0.3–1.1) for transplant vs CR/CRi without transplant. In
other words, while the survival advantage of transplant over
no transplant and that of CR/CRi over non-transplanted
patients not achieving CR/CRi was conﬁrmed, we were not
able to demonstrate a statistically signiﬁcant difference in
survival between patients receiving AlloSCT and those that
were not transplanted but had achieved CR/CRi (p= 0.11)
(Fig. 2a); the latter displayed a median response duration of
3 months (range 0.5 months to 56 months). These obser-
vations were in line with the superior survival seen with
CR/CRi vs no response, among patients receiving intensive
induction chemotherapy (Fig. 3a; p< 0.001); on the other
hand, survival was similar between patients achieving CR
vs CRi (Fig. 3a). Furthermore, among the 24 transplanted
patients in the Mayo cohort, outcome was similar whether
a b
Fig. 2 a Survival data on 248 Mayo Clinic patients with blast-phase myeloproliferative neoplasm, stratiﬁed by speciﬁc treatment strategies; b
Survival data on 162 Italian patients with blast-phase myeloproliferative neoplasm, stratiﬁed by treatment received
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or not CR/CRi was documented at time of transplant
(Fig. 3b; p= 0.6). Overall survival in patients receiving
HMA was similar to those receiving other form of che-
motherapy, in the absence of CR/CRi (p= 0.22); in both
instances, survival was longer than that seen with suppor-
tive care only (p< 0.01), but the latter group of patients
were signiﬁcantly older and presumably suffered from poor
performance status that contributed to treatment selection.
Finally, we examined the prognostic interaction between
baseline risk factors at time of leukemic transformation (i.e.,
high risk karyotype, thrombocytopenia, advanced age and
red cell transfusion need) and speciﬁc treatment groups
stratiﬁed by response categories (i.e., AlloSCT, CR/CRi
without AlloSCT, no transplant/no CR/CRi), in a multi-
variable analysis, and conﬁrmed the inter-independent sur-
vival impact of AlloSCT (HR 0.2, 95% CI 0.1–0.3),
CR/CRi without AlloSCT (HR 0.3, 95% CI 0.2–0.5), high
risk karyotype (HR 1.6, 95% CI 1.1–2.2) and platelet count
< 100× 109/L (HR 1.6, 95% CI 1.1–2.2). Furthermore, we
were intrigued by the possibility that the presence of high
risk karyotype might diminish the value of AlloSCT,
although the difference in survival did not reach
signiﬁcance (Fig. 3c). The favorable survival impact of
transplant and CR/CRi was also suggested in the Italian
patient cohort (Fig. 2b).
Discussion
The current study conﬁrms the dismal prognosis associated
with MPN-BP, identiﬁes parameters of success for short-
term survival and highlights the limited value of current
therapy, including AlloSCT, in securing long-term survival.
We were particularly dismayed with the overall 3-year
survival rate of only 6–11%, conﬁrmed in two independent
patient cohorts; furthermore, the situation has not improved
over the last 15 years, despite the increasing use of more
aggressive treatment approaches, including AML-like
induction chemotherapy and AlloSCT. A number of prac-
tically important observations from the current study
deserve bulleted reiteration; (i) it is highly unlikely for non-
transplant patients managed with supportive care only, or
who do not respond to chemotherapy, to survive for more
than 3 years, and more than 90% might succumb to their
Fig. 3 a Survival data on 66 Mayo Clinic patients with blast-phase
myeloproliferative neoplasm, treated with intensive induction che-
motherapy and stratiﬁed by speciﬁc response categories; b Survival
data on 24 Mayo Clinic patients with blast-phase myeloproliferative
neoplasm, treated with allogeneic stem cell transplantation and
stratiﬁed by speciﬁc response category at time of transplant; c Survival
data on 21 Mayo Clinic patients with blast-phase myeloproliferative
neoplasm who were transplanted and stratiﬁed by the presence or
absence of high risk karyotype
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disease within one year of leukemic transformation; (ii) at
present, AML-like induction chemotherapy is the only
treatment modality, other than AlloSCT, with the potential
to induce CR or CRi, which appears to be a pre-requisite for
improved short-term survival; in this regard, the current
study suggests that the likelihood of attaining CR/CRi is not
undermined by the presence of high risk karyotype, WHO
morphological category or advanced age; (iii) AlloSCT
appears to have an age-independent value in prolonging
short-term survival; however, the current study raises doubt
on the durability of this beneﬁt, beyond 3 years. Further-
more, additional studies are required to clarify the value of
pre-transplant induction chemotherapy, which did not
appear to modify overall outcome in the current study. It is
possible that other factors, such as karyotype, might be
more informative, in this regard (Fig. 3c). The latter
observation also raises the concern regarding the value of
AlloSCT in cytogenetically high risk patients with MPN,
who have not yet transformed into MPN-BP.
The overall experience in the current study is consistent
with the consensus impression from multiple other reports,
which we have summarized in supplemental Table 1, along
with the relevant reference list. Conservative approaches,
such as the use of HMAs, have had limited value, including
a near zero percent chance of achieving CR or CRi and
median response durations of less than one year, which
might have been a little longer in responders. The salutary
effect of AlloSCT has long been suspected and repeatedly
demonstrated by previous studies as well (Supplemental
Table 1). However, many of the relevant studies in this
regard suffer from short follow-up, and observations that are
contrary to our own, including the value of attaining CR
before transplant; [33–35] for example, a retrospective
study in MPN-BP, using the national registry database of
the Japan Society for Hematopoietic Cell Transplantation,
reported a 2-year post-AlloSCT survival rate of 29%,
despite the fact that 82% of the patients were not in
remission at the time of transplant [36]. Regardless, we
would like to emphasize the fact that the number of infor-
mative cases concerning the use of AlloSCT, in the current
study, is simply too small to allow deﬁnitive conclusions to
be made. The issue is further confounded by the retro-
spective nature of the study and the absence of uniformity in
patient selection and pre-transplant treatment approaches.
The issues at hand are more likely to be resolved in the
context of prospective clinical trials of AlloSCT in MPN-
BP. Other limitations of the current study stem from its
retrospective design and the incomplete set of available
information; for example cytogenetic information was
available in only 69% of the patients in the Mayo cohort,
which was a major deterrent from fully appreciating its
effect on transplant outcome.
A number of investigational studies are actively addres-
sing the current dire situation with MPN-BP; in one study of
100 patients with myeloﬁbrosis previously exposed to
JAK1/2 inhibitor therapy, the outcome of 13 patients
transplanted during MPN-BP was not necessarily better
than expected, with a 2-year survival of 32% [37]. Simi-
larly, the JAK1/2 inhibitor ruxolutinib had limited value
during a phase-2 study that included 18 patients with MPN-
BP [38]. Other agents of interest in MPN-BP include
bromo-domain and extra-terminal domain inhibitors
(BETi), CPX-351, which is a liposome formulation of
cytarabine and daunorubicin, targeted therapy against IDH
(enasidenib), CD33 (gemtuzumab ozogomycin) or BCL-2
(venetoclax) [39, 40]. Time will tell whether or not
these new drugs will ultimately make a difference in the
outcome of MPN-BP. In the meantime, the situation is
best addressed by not delaying AlloSCT in MPN patients
who are at risk for premature death or leukemic transfor-
mation [16].
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